Tm Bioscience reports Genzyme Genetics launch of upgraded cystic fibrosis test
Tm Bioscience Corporation announced that Genzyme Genetics launched its upgraded CFplus(TM) cystic fibrosis (CF) mutation analysis which now includes testing for 97 mutations. Genzyme Genetics' new CFplus(TM) assay incorporates technology from Tm Bioscience which was developed in a collaborative effort.
Tm Bioscience's product menu is focused in the fields of human genetic disorders, pharmacogenetics and infectious disease. The Company has commercialized Analyte Specific Reagents and a series of Tag-It(TM) tests(xx) for a variety of genetic disorders. The Company's Tag-It(TM) Cystic Fibrosis Kit is the first multiplexed human disease genotyping test to be cleared by the U.S. Food and Drug Administration as an in vitro device for diagnostic use in the United States. All genetic tests from Tm Bioscience are based on the Tag-It(TM) Universal Array platform, which utilizes a proprietary universal tag system that allows for easy optimization, product development and expansion.
Other news from the department research and development
These products might interest you

Blotting standards and reagents by Cytiva
Western blotting standards and reagents
Blotting the course to effective detection of proteins from sample preparation to analysis

Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation

DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference

Greener Alternative Products by Merck
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Novel insights in MET-proto-oncogene might lead to optimizing cancer treatment - MET inhibitors could have a double-edged effect on tumors
Leprosy strain genotyped from medieval pilgrim at UK burial site - Medieval leprosy victim in UK cemetery was likely a religious pilgrim, possibly from overseas
Johne's_disease
Basilea and Astellas update isavuconazole phase III trial in consultation with FDA
